Cargando…
Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial
INTRODUCTION: Migraine is the most common neurological disorder and one of the major causes of years lived with disability. Its treatment (especially of chronic forms) is often challenging and accompanied with adverse effects. Although new therapeutic approaches have recently emerged (eg, calcitonin...
Autores principales: | Schmidt, Katharina, Kleine-Borgmann, Julian, Holle-Lee, Dagny, Gaul, Charly, Bingel, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230930/ https://www.ncbi.nlm.nih.gov/pubmed/34162645 http://dx.doi.org/10.1136/bmjopen-2020-045969 |
Ejemplares similares
-
Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application
por: Diener, Hans-Christoph, et al.
Publicado: (2022) -
No long-term effects after a 3-week open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized controlled trial
por: Kleine-Borgmann, Julian, et al.
Publicado: (2023) -
Brain-derived neurotrophic factor in primary headaches
por: Fischer, Marlene, et al.
Publicado: (2012) -
Study protocol of Prednisone in episodic Cluster Headache (PredCH): a randomized, double-blind, placebo-controlled parallel group trial to evaluate the efficacy and safety of oral prednisone as an add-on therapy in the prophylactic treatment of episodic cluster headache with verapamil
por: Holle, Dagny, et al.
Publicado: (2013) -
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)